European Journal of Pharmaceutics and Biopharmaceutics 70 (2008) 765–769

Contents lists available at ScienceDirect

European Journal of Pharmaceutics and Biopharmaceutics

journal homepage: www.elsevier.com/locate/ejpb

Research paper

Reduction in burst release of PLGA microparticles by incorporation into cubic phase-forming systems

Abid Riaz Ahmed, Andrei Dashevsky, Roland Bodmeier *

College of Pharmacy, Freie Universität Berlin, Berlin, Germany

ARTICLE INFO

Article history:
Received 30 April 2008
Accepted in revised form 15 July 2008
Available online 23 July 2008

Keywords:
Biodegradable microparticles
Cubic phase
Glycerol monooleate
Initial burst
Poly(lactide-co-glycolide)

ABSTRACT

A high initial burst release of an phosphorothioate oligonucleotide drug from poly(lactide-co-glycolide) (PLGA) microparticles prepared by the w/o/w solvent extraction/evaporation was reduced by incorporating the microparticles into the following glycerol monooleate (GMO) formulations: 1) pure molten GMO, 2) preformed cubic phase (GMO + water) or 3) low viscosity in situ cubic phase-forming formulations (GMO + water + cosolvent). The in situ cubic phase-forming formulations had a low viscosity in contrast to the first two formulations resulting in good dispersability of the microparticles and good syringability/injectability. Upon contact with an aqueous phase, a highly viscous cubic phase formed immediately entrapping the microparticles. A low initial burst and a continuous extended release over several weeks was obtained with all investigated formulations. The drug release profile could be well controlled by the cosolvent composition with the in situ systems.

1. Introduction

Phosphorothioate oligonucleotide drugs have attracted special interest as a novel class of therapeutic agents for the treatment of viral infection, cancers and genetic disorders. However, the oligonucleotides have poor biological stability due to short half-life ranging from 15 to 60 min after oral or systemic administration [1]. In order to improve the in vivo efficacy, repeated administration of oligonucleotide would be required in order to provide a sustained pharmacological effect. The repeated administration can be overcome by encapsulating oligonucleotide within biodegradable polymeric microparticles. The release of oligonucleotides from microparticles would provide the controlled delivery at a predetermined rate to the target tissue over a period of time and protect from degradation (e.g. enzymes), thus providing improved bioavailability.

One challenge in the development of biodegradable microparticles is often a too high initial drug release ("burst effect"), in particular with highly water-soluble drugs [2]. A higher initial drug release reduces the effective lifetime of the system and could lead to toxic effects [3]. This problem is particularly relevant to protein and peptide drugs [4].

The multiple emulsion (w/o/w) solvent evaporation technique has been widely applied for the microencapsulation of macromolecular drugs within biodegradable polymeric microparticles [5–9]. A high initial burst from microparticles prepared by the w/o/w emulsion method is usually attributed to a rapid diffusion of the drug through water-filled pores and channels within the microparticles [10] or to drug present close to the surface [11,12]. In addition, the external and internal morphology of the microparticles is significantly influenced by the initial burst and release behaviour [13].

Approaches to reduce the initial burst include the modification of formulation [9], changing process conditions [14], extraction of the drug close to the surface [15], surface modification [16] or an additional coating [17]. Poly (D,L-lactide-co-glycolide) microspheres of Zn-human growth hormone were suspended in a reverse thermal gelation solution, which formed a gel around the microparticles at body temperature (37 °C). This contributed to a significant reduction of the initial burst [18].

Glycerol monooleate (GMO) forms various lyotropic liquid crystalline structures. Anisotropic (hexagonal and lamellar) or isotropic (very viscous cubic phases) structures are formed depending on the ratio of GMO/water/additive and temperature [19]. The cubic phase is a suitable carrier for both hydrophilic and lipophilic drugs because of its amphiphilic nature [20–25]. GMO is non-toxic, biocompatible and biodegradable [26,27] and shows good chemical and physical stability of incorporated drugs and proteins [25]. Drug release from the cubic phase is diffusion-controlled and follows the square root of time kinetics [22]. However, the cubic phase is highly viscous and thus difficult to handle or to inject. As an alternative, low viscosity three-component formulations composed of GMO:water:cosolvent were developed [23] . Upon injection into aqueous media, the cosolvent leaches out and a viscous cubic phase is formed in situ. The Camurus AB, Sweden have been marketing glycerol monooleate based formulation for Parodontitis use (e.g. Elyzol® dental gel), and several products for parenteral use are in phase II studies.

* Corresponding author. College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany. Tel.: +49 30 83850643; fax: +49 30 83850692.
E-mail address: bodmeier@zedat.fu-berlin.de (R. Bodmeier).

0939-6411/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejpb.2008.07.008

The objective of this study was to reduce the initial burst release of an oligonucleotide model drug from PLGA microparticles by their incorporation into GMO-containing formulations (molten GMO, preformed cubic phase, in situ cubic phase-forming systems).

2. Materials and methods

2.1. Materials

The following materials were used as received and were at least of reagent grade: phosphorothioate oligodeoxynucleotide (ISIS Pharmaceuticals Inc., Carlsbad, CA, USA), poly (D,L-lactide-co-glycolide) (PLGA, Resomer® RG 755, Mw 64,286 Da, inherent viscosity 0.6; Boehringer Ingelheim KG, Ingelheim, Germany), polyvinyl alcohol (PVA, Mowiol® 40–88, Clariant GmbH, Frankfurt, Germany), glycerol monooleate (GMO, GMOrphic® 80; Eastman Chemical Company, Kingsport, TN, USA), polyethylene glycol 300 (PEG 300, Lutrol® 300, BASF AG, Ludwigshafen, Germany), propylene glycol (PG, BASF AG, Ludwigshafen, Germany), ethanol, methylene chloride, potassium dihydrogen phosphate, sodium hydroxide, sodium chloride, sodium azide (Merck KGaA, Darmstadt, Germany), dialysis bag (cellulose ester, MWCO:100,000, Spectra/Por® CE, Spectrum Medical Industries Inc., Houston, Texas, USA).

2.2. Preparation of microparticles by the w/o/w-method

Standard formulation: An aqueous solution of the oligonucleotide (0.033, 0.060 and 0.075 g drug in 0.25 ml water) was emulsified into a solution of the polymer (0.30 g PLGA RG 755 in 4.0 ml methylene chloride) by probe sonication (Sonoplus® HD 250, Bandelin Electronic, Berlin, Germany) for 30 s. This primary w/o emulsion was then dispersed into 800 ml external aqueous phase (0.25% w/v PVA containing 0.25 M NaCl) under propeller stirring (Heidolph Elektro, Kehlheim, Germany) for 5 min and then further agitated for 1 h with a magnetic stirrer (Jankle and Kunkel GmbH & Co., IKA Labortechnik, Staufen, Germany) for the solidification of the polymeric particles by solvent extraction/evaporation. The microparticles were separated from the external aqueous phase by wet sieving (stainless steel test sieves, 50 and 100 μm), washed with 200 ml water, dried in a desiccator for 48 h and then stored in refrigerator.

2.3. Drug content

Triplicate samples of microparticles (10–12 mg, accurately weighed) were dissolved in 8 ml 0.5 M NaOH followed by agitation in a horizontal shaker (IKA HS 501 digital horizontal Shaker, Janke & Kunkel & Co. IKA Labortechnik, Staufen, Germany) for 12 h. The drug concentration in the aqueous phase was determined by UV-spectrophotometry at $\lambda = 260$ nm (Shimadzu UV 2101 PC UV–vis scanning spectrophotometer, Kyoto, Shimadzu Japan) [6]. The polymer did not interfere at the wavelength used. The actual drug loading and encapsulation efficiency were calculated as:

Actual drug loading (%) = (mass extracted drug/mass of microparticles) × 100 %

Encapsulation efficiency (%) = (actual drug loading/theoretical drug loading) × 100 %.

2.4. Incorporation of microparticles into different GMO matrices

Microparticles were incorporated into three different GMO matrices: (1) GMO molten in a water bath at 45 °C and thoroughly mixed with the microparticles (20%, 30% and 40% w/w microparticles); (2) a cubic phase obtained by mixing of molten GMO (3.5 g) and water (1.5 g) on the surface of a Petri-dish by spatula. This cubic phase was transferred into tightly closed glass vials, stored for 24 h at room temperature for equilibration and was subsequently mixed with the microparticles as described above. The phase transformation (cubic to lamellar phase) upon the incorporation of the microparticles was observed under a polarized light microscope (Axioskop, Carl Zeiss Jena GmbH, Jena, Germany); (3) the low viscosity in situ cubic phase-forming formulations were obtained by mixing of molten GMO, water and cosolvents (PEG 300, propylene glycol, ethanol) in glass vials and stored tightly closed for 24 h for equilibration at room temperature (Table 1). Microparticles were dispersed into the formulations prior to drug release experiments. The microparticles and in situ cubic phase-forming formulation were filled in separate syringes. The syringes were connected, and the microparticles were dispersed in the liquid phase by moving the syringe plungers forward and backward 10 times.

2.5. Optical microscopy

The liquid crystalline phases with/without drug or microparticles were identified by polarized light microscopy (Axioskop, Carl Zeiss Jena GmbH, Jena, Germany). The lamellar phase could be identified by its anisotropic textures (birefringence). The cubic phase was of isotropic nature (transparent) under the polarized microscope.

2.6. In vitro drug release

The in vitro drug release was performed ($n = 3$) in 0.1 M phosphate buffer, pH 7.4, with 0.1% sodium azide as preservative in a horizontal shaker (37 °C, 75 spm; GFL 3033, Gesellschaft für Labortechnik GmbH, Burgwedel, Germany). 10–12 mg microparticles (accurately weighed) was placed into 8 ml prewarmed release medium; 0.1–0.2 g (accurately weighed) of GMO or preformed cubic phase containing microparticles was placed in a Teflon sample holder and 0.1–0.2 g of the in situ cubic phase-forming formulations containing microparticles was filled in dialysis bags. The Teflon sample holder and dialysis bags were then immediately put into 25 ml prewarmed release medium and treated as described above. At predetermined time intervals, 2 ml samples were withdrawn and replaced with fresh medium. The drug concentration was measured spectrophotometrically at $\lambda = 260$ nm (Shimadzu UV 2101 PC UV–vis scanning spectrophotometer, Kyoto, Shimadzu Japan) [6].

3. Results and discussion

Microparticles with different oligonucleotide loadings (10%, 17% and 20%) were prepared by the multiple emulsion (w/o/w) solvent evaporation method. The encapsulation efficiency was 95.10 ± 2.43, 89.26 ± 1.12 and 89.35 ± 0.10, respectively. The oligonucleotide-containing microparticles had a high initial burst, which increased with increasing drug loading (Fig. 1). The burst

Table 1
Composition of the in situ cubic phase (ICP) forming formulations

Solvent type	Composition, %		
	Solvent	GMO	Water
EtOH	35	35	30
PEG 300	50	35	15
PG	70	20	10
PEG 300-EtOH*	50	35	15

* Ratio 1:1.